OpenURL Connection Search

Select item for more details and to access through your institution.

Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype.
Published in:
International Journal of Laboratory Hematology, 2012, v. 34, n. 4, p. 417, doi. 10.1111/j.1751-553X.2012.01402.x
By:
- LANGABEER, S. E.;
- O'BRIEN, D.;
- LIPTROT, S.;
- FLYNN, C. M.;
- HAYDEN, P. J.;
- CONNEALLY, E.;
- BROWNE, P. V.;
- VANDENBERGHE, E.
Publication type:
Article
Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor.
Published in:
European Journal of Haematology, 2006, v. 76, n. 3, p. 258, doi. 10.1111/j.1600-0609.2005.00594.x
By:
- O'Donghaile, D.;
- Hayden, P. J.;
- McCarron, S. L.;
- Doyle, E. M.;
- Lawler, M.;
- Browne, P. V.;
- Conneally, E.;
- Vandenberghe, E.;
- McCann, S. R.
Publication type:
Article
Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Published in:
2004
By:
- Swords, R.;
- Hayden, P. J.;
- Molloy, K.;
- Lawlor, M.;
- Browne, P. V.;
- Murphy, P. T.
Publication type:
Letter
A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase.
Published in:
Bone Marrow Transplantation, 2004, v. 34, n. 6, p. 545, doi. 10.1038/sj.bmt.1704638
By:
- Hayden, P. J.;
- Keogh, F.;
- Conghaile, M. Ni.;
- Carroll, M.;
- Crowley, M.;
- Fitzsimon, N.;
- Gardiner, N.;
- Vandenberghe, E.;
- O'Riordan, J.;
- McCann, S. R.
Publication type:
Article
Pure red cell aplasia after a major ABO-mismatched bone marrow transplant for chronic myeloid leukaemia: response to re-introduction of cyclosporin.
Published in:
Bone Marrow Transplantation, 2004, v. 33, n. 4, p. 459, doi. 10.1038/sj.bmt.1704366
By:
- Hayden, P. J.;
- Gardiner, N.;
- Molloy, K.;
- Ryan, J.;
- Lawler, M.;
- McCann, S. R.
Publication type:
Article
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.
Published in:
Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 18, doi. 10.1038/bmt.2011.9
By:
- Douglas, K W;
- Parker, A N;
- Hayden, P J;
- Rahemtulla, A;
- D'Addio, A;
- Lemoli, R M;
- Rao, K;
- Maris, M;
- Pagliuca, A;
- Uberti, J;
- Scheid, C;
- Noppeney, R;
- Cook, G;
- Bokhari, S W;
- Worel, N;
- Mikala, G;
- Masszi, T;
- Taylor, R;
- Treisman, J
Publication type:
Article
Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST.
Published in:
2005
By:
- Hayden, P. J.;
- Crampe, M.;
- Lawler, M.;
- Conneally, E.;
- McCann, S. R.;
- Vandenberghe, E.;
- Browne, P. V.
Publication type:
Letter

Found: 7

Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype.

Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor.

Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.

A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase.

Pure red cell aplasia after a major ABO-mismatched bone marrow transplant for chronic myeloid leukaemia: response to re-introduction of cyclosporin.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST.